Here, our findings of IL-8 regulation by CRABP-II provide a rationale of a potential novel treatment option to target CRABP-II rather than IL-8 and its receptor in PDAC and other cancers where IL-8 is positively regulated by CRABP-II. This evidence concerns the gene CXCL8 and cancer.